Literature DB >> 10704249

Activation of neutral sphingomyelinase by IL-1beta requires the type 1 interleukin 1 receptor.

N N Nalivaeva1, E G Rybakina, I A Kozinets, S N Shanin, T Bartfai.   

Abstract

The cytokine interleukin 1beta (IL-1beta) plays an important role in host defence reactions and neuro-immune interactions but it is still not clear which of the two interleukin 1 receptor subtypes is coupled to activation of neutral sphingomyelinase (nSMase) by IL-1beta. To investigate involvement of neutral sphingomyelinase (nSMase) in central IL-1beta effects we used P(2)fractions of brain cerebral cortex from wild-type mice and mice deficient in the type 1 IL-1 receptor. IL-1beta (human, recombinant) was shown to activate, in a dose-dependent manner, nSMase in the P(2)brain fraction of the wild-type mice while in the knock-out mice the stimulatory effect of IL-1beta on nSMase was absent. In the presence of an IL-1 receptor antagonist (IL-1ra), IL-1beta did not activate nSMase either in the cortex of wild-type or knock-out mice. These data suggest that nSMase, a key enzyme of the sphingomyelin signal transduction pathway, might be involved in IL-1beta signalling in the brain and that activation of the enzyme requires the IL-1 receptor type 1. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10704249     DOI: 10.1006/cyto.1999.0547

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  10 in total

Review 1.  Roles and regulation of neutral sphingomyelinase-2 in cellular and pathological processes.

Authors:  Achraf A Shamseddine; Michael V Airola; Yusuf A Hannun
Journal:  Adv Biol Regul       Date:  2014-10-27

2.  Inhibition of neutral sphingomyelinase 2 reduces extracellular vesicle release from neurons, oligodendrocytes, and activated microglial cells following acute brain injury.

Authors:  Carolyn Tallon; Silvia Picciolini; Seung-Wan Yoo; Ajit G Thomas; Arindom Pal; Jesse Alt; Cristiano Carlomagno; Alice Gualerzi; Rana Rais; Norman J Haughey; Marzia Bedoni; Barbara S Slusher
Journal:  Biochem Pharmacol       Date:  2021-10-20       Impact factor: 5.858

3.  Neural circuits mediating circulating interleukin-1β-evoked fever in the absence of prostaglandin E2 production.

Authors:  Clarissa M D Mota; Christopher J Madden
Journal:  Brain Behav Immun       Date:  2022-04-14       Impact factor: 19.227

4.  A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1beta.

Authors:  Silvia Balosso; Mattia Maroso; Manuel Sanchez-Alavez; Teresa Ravizza; Angelisa Frasca; Tamas Bartfai; Annamaria Vezzani
Journal:  Brain       Date:  2008-10-24       Impact factor: 13.501

5.  Role of IL-1 beta and 5-HT2 receptors in midbrain periaqueductal gray (PAG) in potentiating defensive rage behavior in cat.

Authors:  Suresh Bhatt; Rekha Bhatt; Steven S Zalcman; Allan Siegel
Journal:  Brain Behav Immun       Date:  2007-09-24       Impact factor: 7.217

6.  Ceramide mediates the rapid phase of febrile response to IL-1beta.

Authors:  Manuel Sanchez-Alavez; Iustin V Tabarean; M Margarita Behrens; Tamas Bartfai
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

Review 7.  Regulation of IGF-I function by proinflammatory cytokines: at the interface of immunology and endocrinology.

Authors:  Jason C O'Connor; Robert H McCusker; Klemen Strle; Rodney W Johnson; Robert Dantzer; Keith W Kelley
Journal:  Cell Immunol       Date:  2008-03-05       Impact factor: 4.868

8.  Lipid rafts and Alzheimer's disease: protein-lipid interactions and perturbation of signaling.

Authors:  David A Hicks; Natalia N Nalivaeva; Anthony J Turner
Journal:  Front Physiol       Date:  2012-06-22       Impact factor: 4.566

9.  Inflammation Combined with Ischemia Produces Myelin Injury and Plaque-Like Aggregates of Myelin, Amyloid-β and AβPP in Adult Rat Brain.

Authors:  Xinhua Zhan; Christopher Cox; Bradley P Ander; Dazhi Liu; Boryana Stamova; Lee-Way Jin; Glen C Jickling; Frank R Sharp
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

10.  Pharmacological inhibition of nSMase2 reduces brain exosome release and α-synuclein pathology in a Parkinson's disease model.

Authors:  Chunni Zhu; Tina Bilousova; Samantha Focht; Michael Jun; Chris Jean Elias; Mikhail Melnik; Sujyoti Chandra; Jesus Campagna; Whitaker Cohn; Asa Hatami; Patricia Spilman; Karen Hoppens Gylys; Varghese John
Journal:  Mol Brain       Date:  2021-04-19       Impact factor: 4.041

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.